Looking for a buyer.
Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company’s core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies.
The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting.
They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019–2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years.
The Company’s plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery.
NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
Detailed Information
Facilities: Has headquarters in US – contractors operate nationwide / portable / buyer can be located worldwide.
Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s).
Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas.
Financing: If the price and deal structure is right.
Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth.
Reason for Selling: Growth.
listing type
exclusive representation
exclusive representation
industry
Business Services
Business Services
location
Los Angeles, CA, USA
Los Angeles, CA, USA
revenue
$2,989,000
$2,989,000
ebitda
$1,144,000
$1,144,000
proposed price
$8,400,000
$8,400,000
To download teaser or contact poster, please sign in.
117 views
1 comment
Sign in to see all replies.
Create an account.